You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Express Scripts
Harvard Business School
Mallinckrodt
McKinsey

Last Updated: August 12, 2020

DrugPatentWatch Database Preview

Claims for Patent: RE36939

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: RE36939
Title: Composition for therapy of diseases with ultrasonic and pharmaceutical liquid composition containing the same
Abstract:A booster comprising a plenty of microbubbles of a gas in a liquid, e.g. about 4.times.10.sup.7 cells/ml of microbubbles of a gas having a diameter of 0.1 to 100 .mu.m in a 3 to 5% human serum albumin solution, and a pharmaceutical liquid composition comprising the booster as set forth above and a medicament, which are useful for the therapy of various diseases together with exposure of ultrasonic, where the therapeutic effects of the medicament is enhanced by the application of ultrasound in the presence of the booster.
Inventor(s): Tachibana; Katsuro (Fukuoka, JP), Tachibana; Shunro (Fukuoka, JP)
Assignee: EKOS Corporation (Bothell, WA)
Application Number:08/652,690
Patent Claims:1. A .[.booster.]. .Iadd.composition .Iaddend.for enhancing effects of ultrasound in the therapy of diseases, which comprises:

.Iadd.a liquid; .Iaddend.

.[.a..]. a medicament.Iadd.; .Iaddend.and

.[.b..]. microbubbles of a gas having a diameter of 0.1 to 100 .mu.m.Iadd., .Iaddend..[.in a liquid.]. .Iadd.wherein a majority of the medicament is present outside of the microbubbles.Iaddend..

2. The .[.booster.]. .Iadd.composition .Iaddend.according to claim 1, wherein the microbubbles are formed from air or oxygen gas in the liquid.

3. The .[.booster.]. .Iadd.composition .Iaddend.according to claim 1, wherein the liquid is a 3 to 5% human serum albumin solution.

4. A pharmaceutical liquid composition for the therapy of diseases with application of ultrasound, which comprises:

.Iadd.a liquid; .Iaddend.

.[.a..]. microbubbles of a gas having a diameter of 0.1 to 100 .mu.m.Iadd.; .Iaddend.and

.[.b..]. a medicament selected from the group consisting of thrombolytic agents, hormones, antibiotics and antineoplastic agents.Iadd., .Iaddend..[.in a liquid.]. .Iadd.wherein a majority of the medicament is present outside of the microbubbles.Iaddend..

5. The composition according to claim 4, wherein the microbubbles are formed from air or oxygen gas in the liquid.

6. The composition according to claim 4, wherein the liquid is a 3 to 5% human serum albumin solution. .[.7. The composition according to claim 4, wherein the medicament is a member selected from thromobolytic agents,

hormones, antibiotics, and antineoplastic agents..].8. The composition according to claim 4, wherein the medicament is selected from the group consisting of urokinase, tissue plasminogen activator, insulin,

theophylline, and lidocaine. 9. A method for enhancing the therapeutic effects of a medicament, comprising:

.[.a. applying ultrasound to a pharmaceutical liquid composition according to claim 4 and

b..]. administering .[.said.]. .Iadd.a .Iaddend.pharmaceutical liquid composition .Iadd.comprising a liquid, a medicament, and microbubbles of a gas having a diameter of 0.1 to 100 .mu.m, wherein a majority of the medicament is present outside of the microbubbles; and

applying ultrasound to the pharmaceutical liquid composition.Iaddend.. 10. The method according to claim 9, wherein the liquid composition comprises about 4.times.10.sup.7 cells/ml of microbubbles .[.of a gas having a diameter of 0.1 to 100 .mu.m and a medicament in the liquid.]..

. The method according to claim 10, wherein the liquid is a 3 to 5%

human serum albumin solution. 12. The method according to claim 9, wherein the medicament is selected from the group consisting of urokinase, tissue

plasminogen activator, insulin, theophylline, and lidocaine. 13. A method of dosing subjects with a pharmaceutical preparation by:

.[.a. applying ultrasound to a pharmaceutical liquid composition and.].

.[.b..]. administering .[.said.]. .Iadd.a .Iaddend.pharmaceutical liquid composition comprising .Iadd.a liquid, .Iaddend.microbubbles of a gas having a diameter of 0.1 to 100 .mu.m.Iadd., .Iaddend.and a medicament .[.in a liquid in the therapy of diseases.]. .Iadd.wherein a majority of the medicament is present outside of the microbubbles; and

applying ultrasound to the pharmaceutical liquid composition.Iaddend.. 14. The method of dosing according to claim 13, wherein the microbubbles

are formed from air or oxygen gas in the liquid. 15. The method of dosing according to claim 13, wherein the liquid is a 3 to 5% human serum albumin

solution. 16. The method of dosing according to claim 13, wherein the medicament is selected from the group consisting of urokinase, tissue

plasminogen activator, insulin, theophylline, and lidocaine. .Iadd.17. A composition for enhancing the effects of ultrasound in the therapy of diseases when said ultrasound is administered in conjunction with a medicament, said composition comprising a liquid, a medicament, and microbubbles of a gas made of a shell having a diameter of 0.1 to 100 .mu.m, wherein a majority of the medicament is present outside of the shell and is not incorporated in the shell. .Iaddend..Iadd.18. A composition for enhancing the effects of ultrasound in the therapy of diseases which comprises a liquid, a medicament, and microbubbles of a gas made of a shell having a diameter of 0.1 to 100 .mu.m, wherein at least a majority of the medicament is present outside of the shell.

.Iaddend..Iadd.9. A method for enhancing the therapeutic effects of ultrasound comprising:

creating a mixture comprising a liquid, microbubbles of a gas having a diameter of 0.1 to 100 .mu.m, and a medicament, wherein a majority of the medicament is present outside of the microbubbles; and

applying ultrasound to the mixture. .Iaddend..Iadd.20. The method of claim 19 wherein the mixture is administered in proximity to a diseased part. .Iaddend..Iadd.21. The method of claim 19 wherein the mixture is injected into a blood vessel near a diseased part. .Iaddend..Iadd.22. A method for enhancing the therapeutic effect of a medicament administered to a patient comprising:

administering to the patient a liquid composition comprising microbubbles of a gas having a diameter of 0.1 to 100 .mu.m; and

applying ultrasound to the liquid composition and the medicament, wherein a majority of the medicament is present outside of the microbubbles. .Iaddend..Iadd.23. The method of claim 22 wherein the mixture is injected into a blood vessel near a diseased part. .Iaddend..Iadd.24. A method of enhancing the therapeutic effects of ultrasound of a medicament comprising:

creating microbubbles of a gas having a diameter of 0.1 to 100 .mu.m in a liquid containing the medicament, wherein a majority of the medicament is present outside of the microbubbles; and

applying ultrasound to the microbubbles. .Iaddend..Iadd.25. The method of claim 24 wherein the liquid is administered in the proximity of a diseased part. .Iaddend..Iadd.26. The method of claim 24 wherein the liquid is injected in a blood vessel near the diseased part. .Iaddend.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan3-058970Mar 22, 1991

Details for Patent RE36939

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Microbix Biosystems KINLYTIC urokinase INJECTABLE;INJECTION 021846 001 1978-01-16   Start Trial EKOS Corporation (Bothell, WA) 2011-03-22 DISCN search
Microbix Biosystems KINLYTIC urokinase INJECTABLE;INJECTION 021846 002 1978-01-16   Start Trial EKOS Corporation (Bothell, WA) 2011-03-22 DISCN search
Microbix Biosystems KINLYTIC urokinase INJECTABLE;INJECTION 021846 003 1978-01-16   Start Trial EKOS Corporation (Bothell, WA) 2011-03-22 DISCN search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
McKesson
Colorcon
AstraZeneca
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.